Fusion Antibodies
FAB · AIM · Health Care · mcap £12m · 10.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 05 Oct 26 | Launch of new customer-focused website
Fusion Antibodies launches redesigned customer-focused website to showcase capabilities. |
+0.0% | |
| 22 Sep 26 | Routine | Posting of Annual Report & Notice of AGM | |
| 15 Sep 26 | Results | Final Results
FY2026 revenue £2.1m, gross margin improved to 58.3%, operating loss narrowed to £1.13m despite R&D investment. |
+16.2% |
| 14 Sep 26 | Results | Final Results
FY26 revenue £2.1m, gross margin improved to 53%, operating loss narrowed to £1.13m, OptiMAL® launched. |
−21.3% |
| 09 Sep 26 | Grant of Canadian Patent for OptiMAL
Canadian patent granted for OptiMAL antibody library and design method. |
−2.2% | |
| 09 Sep 26 | Routine | Notice of Results | |
| 06 Aug 26 | Notice of acceptance of patent in Australia
IP Australia issues notice of acceptance for antibody library patent application. |
+2.4% | |
| 20 Jul 26 | Routine | Grant of options | |
| 01 Jul 26 | Holding | Holding(s) in Company | |
| 30 Jun 26 | Routine | Total Voting Rights | |
| 22 Jun 26 | Notice of allowance of patent in Canada
Canadian patent office issues notice of allowance for antibody library patent application. |
+0.0% | |
| 15 Jun 26 | Update on grant-funded DR5 project
DR5 humanised antibody project progressing; grant extended to December 2026; stable cell line developed. |
−2.1% | |
| 02 Jun 26 | Routine | Exercise of options and total voting rights | |
| 11 May 26 | Holding | Holding(s) in Company | |
| 11 May 26 | Grant of patent in Japan
Japan Patent Office grants patent covering antibody library design families and methods. |
+7.4% | |
| 05 May 26 | Trading update | Year-end trading statement
FY2026 revenues £2.13m, gross margin 50%, cash £1.04m; secured pharma contracts and US patent for OptiMAL platform. |
−10.7% |
| 30 Mar 26 | Antibody IP transfer agreement
Fusion transferred background IP ownership to client Finn Therapeutics for £250,000 one-off payment. |
+1.2% | |
| 17 Feb 26 | Director dealing | Director/PDMR Shareholding | |
| 04 Feb 26 | Holding | Holding(s) in Company | |
| 02 Feb 26 | Holding | Holding(s) in Company | |
| 30 Jan 26 | Routine | Total Voting Rights | |
| 27 Jan 26 | Issue of Director Shares
Directors issued 308,720 shares at 13p each in satisfaction of bonus awards. |
−1.9% | |
| 27 Jan 26 | Fundraise | Placing and Subscription to raise approx £1.4m
Fusion Antibodies raises £1.4m through placing and subscription of 11m shares at 13p per share. |
−1.9% |
| 19 Dec 25 | Update on negotiations with NCI regarding OptiMAL
NCI expresses interest in extending OptiMAL collaboration agreement for multiple screening targets. |
−8.2% | |
| 16 Dec 25 | Launch of OptiMAL platform
Fusion launched OptiMAL platform for human antibody discovery at industry conference. |
−7.1% | |
| 11 Dec 25 | Mammalian Display video
Fusion releases video explaining OptiMAL Human Antibody Discovery platform ahead of commercial launch at San Diego conference. |
+5.2% | |
| 25 Nov 25 | Holding | Holding(s) in Company | |
| 24 Nov 25 | Results | Half-year Results
H1 FY2026 revenues fell 30% to £0.84m; loss narrowed to £0.51m; OptiMAL® launch scheduled December 2025. |
−2.1% |
| 21 Nov 25 | Routine | Notice of Results | |
| 13 Nov 25 | OptiMAL Library video
Company releases educational video on OptiMAL antibody library technology ahead of December commercial launch. |
+2.0% | |
| 03 Nov 25 | OptiMAL® R&D Update
OptiMAL® validated for peptide targets; commercial launch planned for December 2025. |
+0.0% | |
| 27 Oct 25 | Holding | Holding(s) in Company | |
| 16 Oct 25 | Routine | Result of AGM | |
| 16 Oct 25 | Trading update | AGM statement and H1 trading update
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the Company's AGM, being held later today, |
+9.4% |
| 08 Oct 25 | Contract win
Fusion selected for multi-target humanisation project with European global pharmaceutical company under MSA. |
−1.6% |
Company filings. Not investment advice.